Recent decisions at the FDA threaten to turn its disagreements with the drugmaker UniQure into another political headache for the Trump administration.
There was a telling exchange during a Thursday media call set up by the Food and Drug Administration to enable a “senior FDA official” — he could only be quoted anonymously — to attack
UniQure
and its experimental treatment for Huntington’s disease.
Robert Langreth, a reporter for Bloomberg, asked the senior official how long he planned to stay at the FDA.
Read the rest…
— Source: STAT News (https://www.statnews.com/2026/03/06/fda-uniqure-rare-disease-huntingtons/)
